Non-Consolidated Financial Results (Japanese GAAP)
for the Six Months Ended June 30, 2026

August 13, 2026

Company Name: Chiome Bioscience Inc. Tokyo Stock Exchange
Stock Code: 4583 URL https://www.chiome.co.jp
Representative: Masamichi Koike, President & CEO
Inquiries: Miseri Tanaka, Head of Corporate Division TEL: +81-3-6383-3561
Scheduled filing date of semi-annual securities report: August 13, 2026
Scheduled dividend payment commencement date: —
Supplementary materials prepared for the quarterly financial results: Yes
Holding of the quarterly financial results explanatory meeting: Yes (For institutional investors and securities analysts)

(Amounts of less than one million yen are rounded down)

1. Financial Results for the Six Months Ended June 30, 2026 (January 1, 2026 to June 30, 2026)

(1) Operating Results (Cumulative)

(% figures are the increase / (decrease) compared with the corresponding period of the previous fiscal year)

	Net Sales		Operating Income		Ordinary Income		Net Income	
	Million yen	%	Million yen	%	Million yen	%	Million yen	%
Six months ended Jun. 30, 2026	273	8.7	(479)	—	(481)	—	(483)	—
Six months ended Jun. 30, 2025	251	(4.5)	(536)	—	(539)	—	(540)	—

	Net Income per Share	Diluted Net Income per Share
	Yen	Yen
Six months ended Jun. 30, 2026	(6.62)	—
Six months ended Jun. 30, 2025	(7.97)	—

Notes: Despite the existence of shares with a dilutive effect, "Diluted Net Income per Share" is not stated because Chiome incurred a loss for each respective period.

(2) Financial Position

	Total Assets	Net Assets	Equity Ratio
	Million yen	Million yen	%
As of Jun. 30, 2026	1,907	1,565	81.9
As of Dec. 31, 2025	1,727	1,122	64.1

(Reference) Equity As of Jun. 30, 2026: 1,562 million yen As of Dec. 31, 2025: 1,107 million yen

2. Dividends

	Annual Dividends				
	1Q-End	2Q-End	3Q-End	FY-End	Total
	Yen	Yen	Yen	Yen	Yen
Fiscal Year Ending Dec. 31, 2025	—	0.00	—	0.00	0.00
Fiscal Year Ending Dec. 31, 2026	—	0.00			
Fiscal Year Ending Dec. 31, 2026 (Forecast)			—	0.00	0.00

Note: Revision to the most recently announced dividend forecast: No

3. Forecasts of Financial Results for the Fiscal Year Ending December 31, 2026 (January 1, 2026 to December 31, 2026)

As it is difficult to provide reasonable estimates for Drug Discovery and Development Business at present, Chiome discloses only business forecasts for Drug Discovery Support Business; net sales ¥600 million. There is no revision to the most recently announced forecasts of financial results.

[Notes]

(1) Application of Special Accounting Practices in the Preparation of Quarterly Financial Statements: No

(2) Changes in Accounting Policies, Changes in Accounting Estimates, and Retrospective Restatements
- 1) Changes in accounting policies in line with revisions to accounting and other standards: No
- 2) Changes in accounting policies other than 1) above: No
- 3) Changes in accounting estimates: No
- 4) Retrospective restatements: No

(3) Number of Shares Issued (Common Stock)

1) Number of shares issued as of the end of the period (including treasury stock)	As of Jun. 30, 2026	78,940,200 shares	As of Dec. 31, 2025	68,453,800 shares
2) Number of treasury stock as of the end of the period	As of Jun. 30, 2026	22,819 shares	As of Dec. 31, 2025	12,149 shares
3) Average number of shares for the period (cumulative total for the period)	Six months ended Jun. 30, 2026	73,037,532 shares	Six months ended Jun. 30, 2025	67,754,994 shares

* Review of the Japanese-language originals of the attached consolidated quarterly financial statements by certified public accountants or audit firms: No

* Explanation Concerning the Proper Use of Financial Results Forecasts and Other Relevant Specific Items

1. Forward-looking statements including forecasts of financial results contained in this report are based on management's assumptions and beliefs that are determined to be reasonable in light of currently available information. Chiome cautions readers that due to a variety of factors actual results may differ materially from forecasts. For the assumptions that underpin financial results forecasts as well as other related items, please refer to the "1. Qualitative Information Regarding Interim Financial Results (3) Explanation of Forward-Looking Statements including Financial Forecasts" on page 5 of this report.
2. Chiome plans to hold a financial results explanatory meeting for institutional investors and securities analysts on August 24, 2026. Supplementary materials will be available on the Chiome's website after the meeting.

Contents

1. Qualitative Information Regarding Interim Financial Results 2
   (1) Overview of Operating Results in the Interim Period under Review 2
   (2) Overview of Financial Position in the Interim Period under Review 4
   (3) Explanation of Forward-Looking Statements including Financial Forecasts 5
2. Interim Financial Statements 6
   (1) Interim Balance Sheets 6
   (2) Interim Statements of Income 8
   (3) Interim Statements of Cash Flows 9
   (4) Notes Concerning Interim Financial Statements 10
      (Notes Regarding Going Concern Assumptions) 10
      (Notes Regarding Substantial Changes in Shareholders' Equity) 10
      (Important Subsequent Events) 10

1. Qualitative Information Regarding Interim Financial Results

(1) Overview of Operating Results in the Interim Period under Review

The Company operates a drug discovery business, mainly developing antibody drugs for areas with high unmet needs, utilizing its antibody generation technology and drug discovery expertise. The Company also operates a drug discovery support business that offers drug discovery technologies and capabilities based on experience and know-how, such as antibody generation and protein expression/purification to pharmaceutical companies and academic institutions. In addition, by leveraging manufacturing expertise, one of its strengths, the Company also operates the Integrated Drug Discovery (IDD) business. The IDD business is expected to contribute to Japan's drug discovery ecosystem. By playing a role in the drug discovery ecosystem through our manufacturing expertise, thereby supporting the Company's business growth.

An overview of the Company's business activities for the interim period is as follows.

In the drug discovery business, Phase I clinical studies are underway for CBA-1535 and CBA-1205; both are house developed therapeutic antibodies for cancer. For CBA-1205, currently evaluation of safety and initial efficacy of CBA-1205 for pediatric cancer patients is underway. Dosing has been completed in patients with melanoma and hepatocellular carcinoma, and data analysis is underway. For CBA-1535, a multispecific antibody targeting cancer, the Company is conducting a stepwise dose-escalation study in patients with solid tumors to evaluate its safety. For other drug discovery pipeline products, the Company continues introductions, scientific validation and discussions with potential out-licensing partners, including at business conferences such as BIO International.

In the drug discovery support business, while focusing on maintaining strong relationships with existing major domestic pharmaceutical companies engaged in antibody drug discovery, the Company continues to promote activities to stabilize its revenue base during the interim period.

In the IDD business launched in the previous fiscal year, which is a platform-based initiative for antibody drug discovery, we are progressing biosimilar-related business with Alfresa Holdings Corporation (Alfresa Holdings) and Kidswell Bio Corporation (Kidswell) and are steadily advancing the joint development of new cell line development for biosimilars. Furthermore, the Company is exploring partnerships and business collaboration with pharmaceutical companies in Japan and abroad, aiming for new biosimilar discoveries in the future, as well as out-licensing opportunities for biosimilars under development. Beyond biosimilars, by utilizing the Company's DoppeLib™ technology and/or Chemistry, Manufacturing and Control (CMC) capabilities, discussions are in progress with potential partner companies to create new business opportunities. Discussions relating to DoppeLib™ are mainly with pharmaceutical companies, and those relating to CMC capabilities are with start-up companies.

The Company's performance during the interim period is as follows: net sales of ¥273,659 thousand (an increase of ¥21,862 thousand year on year), R&D expenses of ¥368,984 thousand (a decrease of ¥26,884 thousand year on year), operating loss of ¥479,717 thousand (operating loss of ¥536,822 thousand in the same period last year), ordinary loss of ¥481,622 thousand (ordinary loss of ¥539,020 thousand in the same period last year), and interim net loss of ¥483,242 thousand (interim net loss of ¥540,290 thousand year on year). R&D expenses, particularly clinical development-related expenses, decreased compared with the same period last year, contributing to reduction in operating loss, ordinary loss and interim net loss year on year.

An overview of the Company's business activities for the interim period is as follows.

1) Drug Discovery Business

- Drug Discovery Pipeline (out-licensed products)

PFKR is a therapeutic antibody candidate targeting CX3CR1, a type of G protein-coupled receptor (GPCR). The Company and the National Center of Neurology and Psychiatry had been progressing with a joint research program. In November 2024, the Company entered into license agreement with Asahi Kasei Therapeutics Corporation (formerly Asahi Kasei Pharma Corporation), which is currently preparing for the initiation of preclinical studies. Under the agreement, milestones in line with development progress were set. The Company will receive milestone payments specified in the agreement whenever a milestone is achieved.

- Drug Discovery Pipeline (In-house programs, out-licensing candidates)

For CBA-1205, the Company is conducting the second part of the Phase I clinical study in Japan. The primary objective of the study is to evaluate safety and tolerability of CBA-1205 in cancer patients. The first part of the study is for patients with solid tumors, and the second part is for patients with melanoma, hepatocellular carcinoma and pediatric cancers. Patient enrollment for the first part has been completed, and CBA-1205 demonstrated a favorable safety profile at doses up to 30mg/kg. Notably, a case was confirmed in which a melanoma patient enrolled in the first part has maintained stable disease (SD) assessment with tumor shrinkage for more than 4 years. In the second part, patient enrollment for melanoma and hepatocellular carcinoma has been completed and analysis of the data are currently ongoing. As in the first part, CBA-1205 demonstrated a favorable safety profile. In a patient with confirmed expression of DLK1, tumour shrinkage of more than 30% (PR) has been observed. Currently patient enrollment for pediatric cancers is in progress. The evaluation of safety and tolerability of pediatric cancer patients with confirmed expression of DLK1 at screening is ongoing. In the screening test up to date, high frequency of DLK1 expression has been observed. Safety evaluation of the initial dose cohort has been completed, and that of the high dose cohort is currently underway.

A Phase I clinical study of CA-1535 in patients with solid tumors is also underway in Japan. At present, evaluation for the safety and tolerability of CBA-1535 as a single agent is in progress and no adverse events raising development concerns have been observed. From June 2026, dosing to the final cohort is in progress in the first part of the study. For CBA-1535, taking competitors' development activities into account, the Company will not conduct the combine part study and prioritize initiatives of out-licensing activities utilizing the clinical data from the single agent study.

PTRY is a Tribody® antibody and is expected to add immune checkpoint inhibitory function on the T-cell engager function of CBA-1535. Its initial evaluations using animal models have shown strong anti-tumor effects. Depending on the development status of CBA-1535, the Company prioritizes out-licensing the product to pharmaceutical companies that can rapidly advance it into clinical development and commercialization, as it may have out-licensing potential at the preclinical stage.

For PCDC, we are conducting out-licensing activities for PCDC, a humanized anti-CDCP2 antibody, with a focus on antibody drug conjugate (ADC) applications. Amid growing global interest in ADCs, we are promoting out-licensing activities with pharmaceutical companies that own ADC technologies.

In addition, the Company is pursuing out-licensing activities for multiple drug discovery projects in the exploratory

phase, including PXLR, while also advancing collaborative research on mRNA x Tribody®, to generate new pipeline candidates through in-house research as well as research collaboration with academic institutions.

- IDD Business

The company has been promoting the creation of drug seeds and making them into intellectual property to expand our pipeline and explorer out-licensing opportunities. In addition, it aims to enhance profitability through this IDD business that utilizes its antibody drug discovery technology and know-how. The Company focused on establishing new collaborations with pharmaceutical and startup companies in drug discovery research and/or biosimilar development. During the interim period, through business alliance with Axcelead Drug Discovery Partners Inc., a new project has started. In addition, the Company's key technology for future IDD business, high-throughput screening methods for bispecific antibodies called DoppeLib™, introductory activities of the technology are in progress with the view of joint research with pharmaceutical companies.

As a result of the above, the Company's performance in the drug discovery business during the interim period is as follows: R&D expenses amounted to ¥368,984 thousand due to the progress of clinical development (a decrease of ¥26,884 thousand year on year), and segment loss of ¥368,984 thousand (segment loss of the same period last year was ¥395,868 thousand).

2) Drug Discovery Support Business

The drug discovery support business contributes to the company's stable earnings. It provides research support services by undertaking antibody production utilizing its proprietary antibody generation platform, and protein preparation works mainly utilizing its protein purification technologies. The Company supports biopharmaceutical research mainly for major domestic pharmaceutical companies such as Ono Pharmaceutical Col, Ltd. and Chugai Pharmaceutical Co., Ltd. The Company's service capabilities are highly recognized by its client companies. Efforts to stabilize the revenue base are ongoing.

The revenue from joint development on cell line development for biosimilars with Alfresa Holdings and Kidswell is recognized as revenue for this business.

The result for the interim period in the drug discovery support business are as follows: sales from research support for pharmaceutical companies decreased, but sales-related to biosimilars increased, resulted in net sales of ¥273,659 thousand (an increase of ¥21,862 thousand year on year), segment profit of ¥158,522 thousand (an increase of ¥19,655 thousand year on year), and a segment margin of 57.9% (target 50%).

(2) Overview of Finance Position in the Interim Period under Review

(i) Assets, Liabilities and Net Assets

(Assets)

Total assets at the end of the interim period amounted to ¥1,907,125 thousand, an increase of ¥179,620 thousand compared with the end of the previous fiscal year.

(Liabilities)

Total liabilities at the end of the interim period amounted to ¥341,264 thousand, a decrease of ¥264,176 thousand compared with the end of the previous fiscal year. This was mainly due to a decrease in corporate bonds.

(Net assets)

Total net assets at the end of the interim period amounted to ¥1,565,861 thousand, an increase of ¥443,796 thousand compared with the end of the previous fiscal year. This was mainly due to increases in share capital and capital reserve from the exercise of stock acquisition rights.

(ii) Cash Flows

The balance of cash and cash equivalents (hereinafter "funds") at the end of the interim period amounted to ¥1,372,022 thousand, an increase of ¥166,995 thousand compared with the end of the previous fiscal year. The status of each cash flow and its main factors are as follows.

(Cash flows from operating activities)

Funds used in operating activities amounted to ¥538,823 thousand during the interim period (¥673,006 thousand used in the same period last year). The main reason for this was recording of an interim loss before tax.

(Cash flows from investing activities)

Funds used in investing activities amounted to ¥3,733 thousand during the interim period. This was mainly due to the acquisition of tangible fixed assets (no change in cash in the same period last year).

(Cash flows from financing activities)

Funds acquired from financial activities during the interim period amounted to ¥709,553 thousand (¥84,678 thousand acquired in the same period last year).

The main breakdown was cash inflows from the issuance of shares upon exercise of stock options and cash outflows due to payments for the redemption of corporate bonds.

(3) Explanation of Forward-Looking Statements including Financial Forecasts

There are no changes to the financial results forecasts for the year ending December 31, 2026, announced on February 10, 2026.

The impact of the Middle East situation on the Company's business is expected to be minimal as of now.

2. Interim Financial Statements

(1) Interim Balance Sheets

Thousand yen

	As of Dec. 31, 2025	As of Jun 30, 2026
Assets		
Current assets		
Cash on hand and in banks	1,205,026	1,372,022
Accounts receivable	71,996	27,631
Inventories	49,412	72,902
Advance payment-trade	135,015	158,377
Consumption taxes receivable	29,520	14,919
Other current assets	55,726	87,338
Total current assets	1,546,698	1,733,191
Non-current assets		
Property and equipment		
Machinery	250,121	247,831
Accumulated depreciation	(213,781)	(212,588)
Machinery, net	36,340	35,242
Tools and equipment	79,857	79,857
Accumulated depreciation	(79,857)	(79,857)
Tools and equipment, net	0	0
Total property and equipment	36,340	35,242
Investments and other assets		
Lease deposits and others	128,191	128,191
Long-term prepaid expenses	16,274	10,500
Others	0	0
Total investments and other assets	144,465	138,691
Total non-current assets	180,806	173,933
Total assets	1,727,504	1,907,125

Thousand yen

	As of Dec. 31, 2025	As of Jun. 30, 2026
Liabilities		
Current liabilities		
Accounts payable, trade	37,442	51,261
Short-term borrowings	86,700	67,500
Accounts payable, other	82,517	75,552
Accrued expenses	14,555	11,838
Income taxes payable	12,553	12,253
Contract liabilities	130,329	60,595
Deposits received	10,787	6,489
Total Current liabilities	374,885	285,491
Non-current liabilities		
Asset retirement obligations	55,554	55,773
Bonds payable	175,000	—
Total non-current liabilities	230,554	55,773
Total liabilities	605,440	341,264
Net assets		
Shareholders' equity		
Capital stock	1,085,523	1,554,710
Capital reserve	2,025,797	2,494,984
Retained earnings	(2,003,555)	(2,486,798)
Treasury stock	(292)	(310)
Total shareholders' equity	1,107,473	1,562,585
Share acquisition rights	14,591	3,275
Total net assets	1,122,064	1,565,861
Total liabilities and net assets	1,727,504	1,907,125

(2) Interim Statement of Income

Thousand yen

	Six Months Ended Jun. 30, 2025 (Jan. 1, 2025 to Jun. 30, 2025)	Six Months Ended Jun. 30, 2026 (Jan. 1, 2026 to Jun. 30, 2026)
Net sales	251,796	273,659
Cost of sales	112,930	115,137
Gross profit	138,866	158,522
Selling, general and administrative expenses		
Research and development expenses	395,868	368,984
Other, net	279,819	269,254
Total selling, general and administrative expenses	675,688	638,239
Operating loss	△536,822	△479,717
Non-operating income		
Interest income	910	1,154
Foreign exchange gains	220	286
Other, net	132	155
Total non-operating income	1,263	1,596
Non-operating expenses		
Interest expenses	1,940	605
Share issuance cost	1,521	2,896
Other, net	－	0
Total non-operating expenses	3,462	3,502
Ordinary loss	(539,020)	(481,622)
Extraordinary income		
Gain on reversal of share acquisition rights	350	－
Total extraordinary income	350	－
Loss before income taxes	(538,670)	(481,622)
Income taxes-current	1,620	1,620
Total income taxes	1,620	1,620
Net loss	(540,290)	(483,242)

(3) Interim Statements of Cash Flows

Thousand yen

	Six Months Ended Jun. 30, 2025 (Jan. 1, 2025 to Jun. 30, 2025)	Six Months Ended Jun. 30, 2026 (Jan. 1, 2026 to Jun. 30, 2026)
Cash flows from operating activities		
Loss before income taxes	(538,670)	(481,622)
Depreciation and amortization	—	4,831
Decrease (increase) in notes and accounts receivable-trade	11,689	44,364
Decrease (increase) in inventories	(495)	(23,489)
Decrease (increase) in advance payments	(2,249)	(23,362)
Decrease (increase) in consumption taxes refund receivable	8,335	14,601
Increase (decrease) in notes and accounts payable-trade	9,632	13,818
Increase Decrease in contract liabilities	—	(69,733)
Increase (decrease) in accounts payable-other	(75,231)	(6,965)
Increase (decrease) in accrued expenses	(18,124)	(2,717)
Other, net	(64,190)	(6,059)
Subtotal	(669,305)	(536,332)
Interest income received	771	978
Interest paid	(1,940)	(605)
Income taxes paid	(3,240)	(3,240)
Income taxes refund	708	376
Net cash used in operating activities	(673,006)	(538,823)
Cash flows from investing activities		
Purchase of property plant and equipment	—	3,723
Net cash provided by investing activities	—	3,723
Cash flows from financing activities		
Decrease in short term loans payable	(21,000)	(19,200)
Proceeds From Issuance of Bonds	—	(175,000)
Proceeds from issuance of common shares	105,678	903,771
Other, net	—	(18)
Net cash provided by (used in) financing activities	84,678	709,553
Net increase (decrease) in cash and cash equivalents	(588,328)	166,995
Cash and cash equivalents as of the beginning of the year	2,063,280	1,205,026
Cash and cash equivalents as of the end of the period	1,474,952	1,372,022

(4) Notes to Interim Financial Statements

(Notes to Going Concern Assumptions)

Not applicable.

(Notes on Substantial Changes in Shareholders' Equity)

During the second cumulative period, the balance of capital stock and capital reserve increased separately by ¥469,186 thousand mainly due to exercise of the Subscription Rights to Shares. As a result, as of June 30, 2026, the balance of capital stock and capital reserve came to ¥1,554,710 thousand and ¥2,494,984 thousand, respectively.

(Important Subsequent Events)

Capital Increase Attributed to the Exercise of Subscription Rights to Shares

After the end of the interim period and up to July 31, 2026, a portion of the 23rd stock acquisition rights were exercised. The summary of the exercised stock acquisition rights is as follows.

(1) Type and number of shares issued: Common stock, 2,209,800 shares

(2) Increased capital stock: ¥75,375 thousand

(3) Increased legal capital reserve: ¥75,375 thousand

As a result, as of July 31, 2026, the total number of the common stock issued is 81,150,000 shares. The capital stock and capital reserve are ¥1,630,085 thousand and ¥2,570,359 thousand respectively